Skip to main content
Fig. 2 | BMC Pulmonary Medicine

Fig. 2

From: Comparison of ceftriaxone plus macrolide and ampicillin/sulbactam plus macrolide in treatment for patients with community-acquired pneumonia without risk factors for aspiration: an open-label, quasi-randomized, controlled trial

Fig. 2

Time-course analyses of body temperature (a), white blood cell (WBC) count (b), and C-reactive protein (CRP) levels (c) in the modified intention-to-treatment (MITT) population. Data are expressed as mean ± standard deviation (SD). The solid line shows ceftriaxone (CTRX), and the broken line shows ampicillin/sulbactam (ABPC/SBT). No significant difference was seen between the two groups in BT, WBC count or CRP levels by paired t-test

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us